RAD-140
RAD-140. Developed by Radius Health as a non-steroidal AR agonist for cancer cachexia + breast cancer. High AR selectivity with… Oral half-life 45 h.
Developed by Radius Health as a non-steroidal AR agonist for cancer cachexia + breast cancer. High AR selectivity with anabolic:androgenic ratio ~90:1 in preclinical models. Clinical development halted; research/illicit use continues.
PK: MY PRIOR IS REFUTED — THE HALF-LIFE IS VERBATIM AND PROPERLY SOURCED. Unlike lgd-4033, ostarine and mk-677, this record cites a real phase-1 in twenty-two patients that states the number outright: "The half-life (t1/2) of 44.7 hours supported QD dosing". AND THE DOSE BLOCK IS NOT THE lgd-4033 DEFECT EITHER: that trial escalated to a maximum tolerated dose well ABOVE anything this record simulates, so unlike the SARM next door it is not asserting a dose no human has received. WHAT IS MISSING IS THE VOLUME AND THE BIOAVAILABILITY, so the curve is rendered against thirty-five litres and 0.9 — neither of which that abstract states, and neither of which I could source. LOGGED RATHER THAN INVENTED. The record is kept because the elimination it describes is real and sourced.
Pharmacokinetics
- Oral — t½ 44.7 h
Sources: PMID:34565686